BridgeBio Pharma, Inc.
BBIO · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Market Cap | $9,895 | $8,227 | $6,573 | $5,198 |
| - Cash | $643 | $749 | $541 | $681 |
| + Debt | $9 | $2,677 | $1,858 | $1,731 |
| Enterprise Value | $9,261 | $10,154 | $7,891 | $6,248 |
| Revenue | $121 | $111 | $117 | $6 |
| % Growth | 9.2% | -5.2% | 1,882.9% | – |
| Gross Profit | $114 | $107 | $114 | $4 |
| % Margin | 94.6% | 96.7% | 97.7% | 64.6% |
| EBITDA | -$173 | -$143 | -$126 | -$235 |
| % Margin | -143.6% | -129.1% | -108.2% | -3,996.1% |
| Net Income | -$183 | -$182 | -$167 | -$265 |
| % Margin | -151.4% | -164.5% | -143.5% | -4,506.1% |
| EPS Diluted | -0.96 | -0.95 | -0.88 | -1.4 |
| % Growth | -1.1% | -8% | 37.1% | – |
| Operating Cash Flow | -$110 | -$81 | -$199 | -$195 |
| Capital Expenditures | -$0 | -$5 | -$2 | -$3 |
| Free Cash Flow | -$110 | -$86 | -$201 | -$199 |